Please assess the completion status of the following clinical trial:

Trial Title: Study on Performance and Safety of Sentinox in the Prevention of Acute Respiratory Infections (ARI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. ICF signed.~2. Males and females aged ≥ 18 years and \<64 years at the time of the signature of the ICF.~3. Subjects who are willing to comply with the requirements of the study protocol, attend scheduled visits and calls for the duration of the study by telephone contact and install the Mobile App to use the e-diary.~Exclusion Criteria:~1. Reporting of any symptoms of ARI in the 15 days preceding the Visit 1.~2. Reporting the intake of any drugs, among antiviral or antibacterial therapies, that may interfere with the study results in the 15 days preceding the Visit 1.~3. Presence of any relevant organic, systemic or metabolic disease (particularly significant history of cardiac, renal, neurological, psychiatric, oncology, endocrinology, metabolic or hepatic disease).~4. Immune system illnesses.~5. Known drug and/or alcohol abuse.~6. Individuals who are cognitively impaired and/or who are unable to give informed consent.~7. Ongoing or prior participation in any other clinical trial of an experimental treatment within 30 days from Visit 1.~8. Concurrent or planned treatment with other agents with actual or possible direct antiviral/antibacterial activity.~9. Positive pregnancy test or breastfeeding woman.~10. Known hypersensitivity to the study treatment, its metabolites, or formulation excipient.~11. History of severe drug and / or food allergies.~12. Any condition that, in the opinion of the Investigator, would complicate or compromise the study or well-being of the Subject

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 63 Years
- Healthy Volunteers: t

Study Arms:
- Group A: treatment with Sentinox performed 3 times/day for 21 days (Type: EXPERIMENTAL): treatment with Investigational Medical Device (IMD) performed 3 times/day for 21 days at 8 am, 2 pm and 8 pm
- Group B:no Sentinox treatment (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).